Huakang Biomedical Holdings Company Limited (HK:8622)

:8622

8622

Huakang Biomedical Holdings Company Limited

RESEARCH TOOLSreports

Want to see HK:8622 full AI Analyst Report?

Huakang Biomedical Holdings Company Limited (8622) Price & Analysis

0 Followers

8622 Stock Chart & Stats

HK$0.42

HK$0.01(7.32%)

At close: Jan 09 4:00 PM EST

HK$0.42

HK$0.01(7.32%)

Day’s Range― - ―

52-Week RangeHK$0.29 - HK$0.75

Previous CloseN/A

Volume952.00K

Average Volume (3M)2.14M

Market Cap

HK$167.53M

Enterprise ValueHK$113.54M

Total Cash (Recent Filing)HK$36.73M

Total Debt (Recent Filing)HK$6.42M

Price to Earnings (P/E)―

Beta0.32

Next Earnings

Aug 11, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.00

Shares Outstanding515,472,000

10 Day Avg. Volume1,472,000

30 Day Avg. Volume2,141,866

Financial Highlights & Ratios

PEG Ratio-2.40

Price to Book (P/B)3.83

Price to Sales (P/S)6.93

P/FCF Ratio-59.52

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

High Gross MarginA ~63% gross margin indicates robust product-level economics and pricing power in the company's portfolio. Over the medium term this margin provides a structural buffer to absorb SG&A and R&D, enabling a clear pathway to operating leverage if fixed costs are controlled and revenue growth continues.

Modest But Positive Revenue GrowthConsistent year-over-year top-line growth demonstrates ongoing market demand and commercial traction in its specialty/generic segment. Over 2–6 months this trend supports scaling of profitable products and increases the likelihood that fixed-cost absorption and margin expansion are achievable with disciplined cost management.

Low Leverage / Conservative Balance SheetA low debt-to-equity ratio materially reduces refinancing and interest-rate risk, giving the company financial flexibility to fund operations or R&D. This conservative capital structure is a durable strength that lowers bankruptcy risk and supports strategic options (e.g., capital raises, partnerships) while losses are addressed.

Bears Say

Persistent Operating LossesChronic operating losses (operating margin ~-28%) indicate the business has not yet converted strong gross economics into profitable operations. Over months this continues to erode equity, reduces management flexibility, and makes achievement of sustainable profitability contingent on significant cost restructuring or faster revenue scaling.

Negative Operating And Free Cash FlowNegative operating and free cash flow across recent years means the company is consuming cash to run the business. This structural cash burn increases reliance on balance-sheet resources or external financing, raising dilution or debt risk and constraining the firm's ability to invest in growth initiatives or R&D over the medium term.

Declining Equity And Negative ROEFalling shareholder equity and a negative return on equity highlight cumulative losses that diminish shareholder value and limit capital efficiency. Persisting negative ROE undermines investor confidence and makes long-term capital attraction harder, which can impede expansion plans or strategic investments.

8622 FAQ

What was Huakang Biomedical Holdings Company Limited’s price range in the past 12 months?

Huakang Biomedical Holdings Company Limited lowest stock price was HK$0.28 and its highest was HK$0.75 in the past 12 months.

What is Huakang Biomedical Holdings Company Limited’s market cap?

Huakang Biomedical Holdings Company Limited’s market cap is HK$167.53M.

When is Huakang Biomedical Holdings Company Limited’s upcoming earnings report date?

Huakang Biomedical Holdings Company Limited’s upcoming earnings report date is Aug 11, 2026 which is in 82 days.

How were Huakang Biomedical Holdings Company Limited’s earnings last quarter?

Huakang Biomedical Holdings Company Limited released its earnings results on Mar 27, 2026. The company reported -HK$0.006 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.006.

Is Huakang Biomedical Holdings Company Limited overvalued?

According to Wall Street analysts Huakang Biomedical Holdings Company Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Huakang Biomedical Holdings Company Limited pay dividends?

Huakang Biomedical Holdings Company Limited does not currently pay dividends.

What is Huakang Biomedical Holdings Company Limited’s EPS estimate?

Huakang Biomedical Holdings Company Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Huakang Biomedical Holdings Company Limited have?

Huakang Biomedical Holdings Company Limited has 515,472,000 shares outstanding.

What happened to Huakang Biomedical Holdings Company Limited’s price movement after its last earnings report?

Huakang Biomedical Holdings Company Limited reported an EPS of -HK$0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.333%.

Which hedge fund is a major shareholder of Huakang Biomedical Holdings Company Limited?

Currently, no hedge funds are holding shares in HK:8622

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Huakang Biomedical Holdings Company Limited Stock Smart Score

Underperform

Technicals

Fundamentals

Return on Equity

-11.77%

Trailing 12-Months

Asset Growth

6.89%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Huakang Biomedical Holdings Company Limited

Huakang Biomedical Holdings Company Limited, an investment holding company, engages in the research, development, manufacture, marketing, and sale of in-vitro diagnostic (IVD) reagents in the People's Republic of China. It offers male and female fertility IVD, parasite antibody detection, and Epstein-Barr virus antibody detection reagents; auxiliary reproductive supplies and equipment; and healthcare products and supplements under the Nutronic brand to customers, as well as through online and offline platforms and channels. The company sells its products directly to hospitals and medical institutions, as well as to distributors. Huakang Biomedical Holdings Company Limited was founded in 1992 and is headquartered in Wan Chai, Hong Kong.